W Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Malaria Research Institute, Johns Hopkins University, Baltimore, Maryland, USA.
Mem Inst Oswaldo Cruz. 2011 Aug;106 Suppl 1(0 1):172-8. doi: 10.1590/s0074-02762011000900022.
CD8+ T cells against malaria liver stages represent a major protective immune mechanism against infection. Following induction in the peripheral lymph nodes by dendritic cells (DCs), these CD8+ T cells migrate to the liver and eliminate parasite infected hepatocytes. The processing and presentation of sporozoite antigen requires TAP mediated transport of major histocompatibility complex class I epitopes to the endoplasmic reticulum. Importantly, in DCs this process is also dependent on endosome-mediated cross presentation while this mechanism is not required for epitope presentation on hepatocytes. Protective CD8+ T cell responses are strongly dependent on the presence of CD4+ T cells and the capacity of sporozoite antigen to persist for a prolonged period of time. While human trials with subunit vaccines capable of inducing antibodies and CD4+ T cell responses have yielded encouraging results, an effective anti-malaria vaccine will likely require vaccine constructs designed to induce protective CD8+ T cells against malaria liver stages.
CD8+ T 细胞对疟原虫肝期的反应代表了针对感染的主要保护免疫机制。在树突状细胞 (DCs) 在周围淋巴结中诱导后,这些 CD8+ T 细胞迁移到肝脏并消除寄生虫感染的肝细胞。裂殖子抗原的加工和呈递需要 TAP 介导的将主要组织相容性复合体 I 表位转运到内质网。重要的是,在 DCs 中,这个过程也依赖于内体介导的交叉呈递,而这个机制对于肝细胞上的表位呈递不是必需的。保护性 CD8+ T 细胞反应强烈依赖于 CD4+ T 细胞的存在和裂殖子抗原持续存在的时间。虽然具有诱导抗体和 CD4+ T 细胞反应能力的亚单位疫苗的人体试验取得了令人鼓舞的结果,但有效的抗疟疾疫苗可能需要设计用于诱导针对疟疾肝期的保护性 CD8+ T 细胞的疫苗构建体。